{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:52:51Z","timestamp":1772434371869,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973181"],"award-info":[{"award-number":["81973181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Provincial Key research and development project","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}]},{"name":"Shandong Provincial Key research and development project","award":["2019JZZY021011"],"award-info":[{"award-number":["2019JZZY021011"]}]},{"DOI":"10.13039\/100000008","name":"National Science and Technology Major Projects for \"Major New Drugs Innovation and Development\"","doi-asserted-by":"publisher","award":["2019ZX09301126"],"award-info":[{"award-number":["2019ZX09301126"]}],"id":[{"id":"10.13039\/100000008","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foreign cultural and educational experts Project","award":["GXL20200015001"],"award-info":[{"award-number":["GXL20200015001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Significantly, rilpivirine is three fold more potent than etravirine. Once-daily, it is used with a low oral dose (25\u00a0mg\/tablet), decreasing the drug administration and bringing a better choice to the patients. However, there are many shortcomings in the existing synthesis route of RPV, such as the high cost, prolonged reaction time and low yield (18.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This article describes our efforts to develop an efficient and practical microwave-promoted method to synthesize rilpivirine using less toxic organic reagents and low boiling solvents. The last step's reaction time decreased from 69\u00a0h to 90\u00a0min through this optimized synthetic procedure, and the overall yield improved from 18.5 to 21%. In addition, the yield of intermediate\n                      <jats:bold>3<\/jats:bold>\n                      increased from 52 to 62% compared to the original patent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, through a series of process optimization, we have developed a practical synthesis method of rilpivirine, which is easy to scale with higher yield and shorter reaction time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13065-021-00749-y","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T06:03:05Z","timestamp":1617343385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The development of an effective synthetic route of rilpivirine"],"prefix":"10.1186","volume":"15","author":[{"given":"Tao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiapei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasulu","family":"Cherukupalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"issue":"5","key":"749_CR1","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.apsb.2019.08.013","volume":"10","author":"D Kang","year":"2020","unstructured":"Kang D, Feng D, Ginex T, Zou J, Wei F, Zhao T, Huang B, Sun Y, Desta S, De Clercq E et al (2020) Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharm Sin B 10(5):878\u2013894","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"749_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","volume":"10","author":"Y Wu","year":"2020","unstructured":"Wu Y, Tang C, Rui R, Yang L, Ding W, Wang J, Li Y, Lai CC, Wang Y, Luo R et al (2020) Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors. Acta Pharm Sin B 10(3):512\u2013528","journal-title":"Acta Pharm Sin B"},{"issue":"Suppl 1","key":"749_CR3","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/med.20241","volume":"33","author":"P Zhan","year":"2013","unstructured":"Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X (2013) HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 33(Suppl 1):E1-72","journal-title":"Med Res Rev"},{"issue":"7","key":"749_CR4","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","volume":"59","author":"P Zhan","year":"2016","unstructured":"Zhan P, Pannecouque C, De Clercq E, Liu X (2016) Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem 59(7):2849\u20132878","journal-title":"J Med Chem"},{"issue":"2","key":"749_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.coviro.2013.03.014","volume":"3","author":"K Das","year":"2013","unstructured":"Das K, Arnold E (2013) HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr Opin Virol 3(2):119\u2013128","journal-title":"Curr Opin Virol"},{"issue":"4","key":"749_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1073\/pnas.1720975115","volume":"115","author":"N Sluis-Cremer","year":"2018","unstructured":"Sluis-Cremer N (2018) Future of non-nucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci USA. 115(4):637\u2013638","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"749_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1021\/acsmedchemlett.8b00054","volume":"9","author":"D Kang","year":"2018","unstructured":"Kang D, Wang Z, Zhang H, Wu G, Zhao T, Zhou Z, Huo Z, Huang B, Feng D, Ding X et al (2018) Further exploring solvent-exposed tolerant regions of allosteric binding pocket for novel HIV-1 NNRTIs discovery. ACS Med Chem Lett 9(4):370\u2013375","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"749_CR8","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1021\/jm1002233","volume":"53","author":"EB Lansdon","year":"2010","unstructured":"Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, Birkus G, Kutty N, Liu X (2010) Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem 53(10):4295\u20134299","journal-title":"J Med Chem"},{"issue":"2","key":"749_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/jac\/dks404","volume":"68","author":"M Sharma","year":"2013","unstructured":"Sharma M, Saravolatz LD (2013) Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother 68(2):250\u2013256","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"749_CR10","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1073\/pnas.0711209105","volume":"105","author":"K Das","year":"2008","unstructured":"Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E (2008) High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A. 105(5):1466\u20131471","journal-title":"Proc Natl Acad Sci U S A."},{"key":"749_CR11","unstructured":"Guillemont JEG, Palandjian P, De Jonge MR, Koymans LMH, Vinkers HM, Daeyaert FFD, Heeres J, Van Aken KJA, Lewi PJ, Janssen PAJ (2003) WO 03016306 Feb 2003"},{"key":"749_CR12","unstructured":"Guillemont JEG, Stevens PTA, Copmans AH, Peeters J, Stappers AE, Vandecruys RPG, Stoffels P (2006) US 20060111379 A1 May 2006"},{"issue":"3","key":"749_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/op8000383","volume":"12","author":"D Schils","year":"2008","unstructured":"Schils D, Stappers F, Solberghe G et al (2008) Ligandless Heck coupling between a halogenated aniline and acrylonitrile catalyzed by Pd\/C: development and optimization of an industrial-scale Heck process for the production of a pharmaceutical intermediate. Org Process Res Dev 12(3):530\u2013536","journal-title":"Org Process Res Dev"},{"key":"749_CR14","unstructured":"Reddy BP, Reddy KR, Reddy DM, Reddy AVN, Krishna BV. (2012) WO 2012147091 Nov2012"},{"issue":"11","key":"749_CR15","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1080\/00397919708006796","volume":"27","author":"J Spychala","year":"1997","unstructured":"Spychala J (1997) A facile preparation of N2-arylisocytosines. Synth Commun 27(11):1943\u20131949","journal-title":"Synth Commun"},{"issue":"23","key":"749_CR16","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1016\/j.bmc.2011.10.002","volume":"19","author":"SX Gu","year":"2011","unstructured":"Gu SX, Yang SQ, He QQ, Ma XD, Chen FE, Dai HF, Clercq ED, Balzarini J, Pannecouque C (2011) Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs. Bioorg Med Chem 19(23):7093\u20137099","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"749_CR17","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1039\/C9OB00032A","volume":"17","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Liu T, Wu G, Kang D, Fu Z, Wang Z, De Clercq E, Pannecouque C, Zhan P, Liu X (2019) Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Org Biomol Chem 17(12):3202\u20133217","journal-title":"Org Biomol Chem"},{"key":"749_CR18","unstructured":"Schils DPR, Stappers AE (2006) WO 2006125809 Nov 2006"},{"key":"749_CR19","unstructured":"Schils DPR, Willems JJM, Medaer BPAMJ, Pasquier ETJ, Janssen PAJ, Heeres J, Leenders RGG (2004) WO 2004016581 Feb 2004"},{"key":"749_CR20","unstructured":"Hajicek J, Slavikova M, Zebula J (2016) WO 2016116074 (A1) Jul 2016"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-021-00749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13065-021-00749-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-021-00749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T06:03:12Z","timestamp":1617343392000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-021-00749-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1186\/s13065-021-00749-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-137675\/v1","asserted-by":"object"}]},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"29 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that the copyright belongs to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}